Washington, DC Researchers from Georgetown University Medical Center's Memory Disorders Program are directing the first U.S. study to determine whether huperzine A, derived from the Chinese club moss plant Huperzia serrata, improves cognitive function in people with Alzheimer's disease (AD). The study, which is recruiting participants at 28 sites across the country, is jointly funded by the National Institutes of Health and Neuro-Hitech Pharmaceuticals, Inc.
Huperzine A, a naturally occurring cholinesterase inhibitor, has been used in Chinese folk medicine for the treatment of fevers and inflammation. Although also commonly used in China to treat Alzheimer's, there have been no controlled clinical trials assessing its toxicity and efficacy outside of China. Chinese studies have suggested that huperzine A is well tolerated and effective.
Paul Aisen, M.D., professor of neurology and leader of the new multi-site study, says huperzine A shows great promise as a treatment for AD. "Based on studies in China, huperzine A may be more effective and better tolerated than currently prescribed drugs for Alzheimer's Disease. In addition, laboratory studies suggest that huperzine may have unique effects that could slow down the progression of the disease."
Huperzine A is currently available in the U.S. and is used by some American physicians to treat A.D. The herb is classified as a nutriceutical by the U.S. Food and Drug Administration, does not require a prescription and is contained in some products sold in health food stores and pharmacies.
The huperzine A study will enroll approximately 150 participants, age 55 or older, with mild to moderate A.D. The trial focuses on individuals who have not found currently approved cholinesterase inhibitors (including Aricept, Reminyl, Exelon or Cognex), effective or tolerable. Cholinesterase inhibitors have been proven to relieve memory impairment and other symptoms associated with A.D.
As Page: 1 2 Related medicine news :1
Contact: Liz McDonald
Georgetown University Medical Center
. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections2
. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation3
. Helicopter flight trials for EGNOS4
. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy5
. GSK announces launch of largest ever Phase III trial in lung cancer treatment6
. Bias in statin trials, failure to control malaria, and more7
. International journal group updates guidelines on registration of clinical trials8
. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference9
. Childrens Hospital and Pitt lead national trial of hypothermia to treat pediatric brain injury10
. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema11
. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007